Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Share:
Related BMY
Bristol-Myers Squibb Target, Estimates Under Review At Goldman Sachs
Earnings Scheduled For April 28, 2016
A Prescription For High Risk Fever (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Latest Ratings for BMY

DateFirmActionFromTo
Apr 2016Societe GeneraleInitiates Coverage onSell
Mar 2016JefferiesMaintainsHold
Jan 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!